Verteporfin
Other / unclassified targets YAP1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | VISUDYNE | — | 2001-08-22 – 2008-06-30 | fda.gov ↗ |
| Approved | EU (EMA) | Visudyne | — | 2000-07-27 | europa.eu ↗ |
| Approved | US (FDA) | VISUDYNE | — | 2000-04-12 | fda.gov ↗ |
Trials 45
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-02-23 | SpectraCure AB | Regulatory Approval for clinical study at Skåne University Hospital spectracure.com ↗
The Swedish Medicines Agency and the Ethics Review Authority have approved the study. |
| 2017-08-25 | SpectraCure AB | Results Full drug dose achieved in prostate trial spectracure.com ↗
In the study, the drug dose (Verteporfin) has been progressively increased in three steps, and no significant adverse reactions have been observed. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-02-23 | SpectraCure AB | Approval for clinical study at Skåne University Hospital spectracure.com ↗ |
| 2017-08-25 | SpectraCure AB | Full drug dose achieved in prostate trial spectracure.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 63 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | verteporfin | “This research study was designed to determine the effect on port wine stains (PWS) of liposomal benzoporphyrin derivative monoacid (BPD-MA) termed verteporfin by intravenous...” NCT00556946 ↗53“The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a...” NCT00802126 ↗ “PDT involves the use of a photo-activated chemotherapeutic agent, benzoporphyrin derivative (verteporfin/Visudyne) given intravenously that when stimulated by non-thermal...” NCT02464761 ↗ “In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence” NCT01968486 ↗ “Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2” NCT03941587 ↗ “Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion” NCT04429139 ↗ “Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)” NCT00680498 ↗ “Verteporfin photodynamic therapy acts through occluding newly formed vessels.” NCT00429962 ↗ “Rescue treatment: Verteporfin photodynamic therapy” NCT02072408 ↗ |
| Known as | BPD-MA | “This research study was designed to determine the effect on port wine stains (PWS) of liposomal benzoporphyrin derivative monoacid (BPD-MA) termed verteporfin by intravenous...” NCT00556946 ↗ |
| Known as | CL 318,952 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314346 ↗ |
| Known as | liposomal benzoporphyrin derivative monoacid | “This research study was designed to determine the effect on port wine stains (PWS) of liposomal benzoporphyrin derivative monoacid (BPD-MA) termed verteporfin by intravenous...” NCT00556946 ↗ |
| Known as | Verteporfin = Visudyne | “Verteporfin = Visudyne” NCT00359164 ↗ |
| Known as | Verteporfin for Injection | “Verteporfin for Injection (VFI), photosensitizing drug” NCT06807359 ↗ |
| Known as | Verteporfina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314346 ↗ |
| Known as | Verteporfine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314346 ↗ |
| Known as | VFI | “Verteporfin for Injection (VFI), photosensitizing drug” NCT06807359 ↗ |
| Known as | Visudyne | “PDT involves the use of a photo-activated chemotherapeutic agent, benzoporphyrin derivative (verteporfin/Visudyne) given intravenously that when stimulated by non-thermal...” NCT02464761 ↗17“Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1” NCT00570193 ↗ “Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion” NCT04429139 ↗ “ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection” NCT01360151 ↗ “Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer.” NCT02872064 ↗ “combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis)” NCT01256580 ↗ “Photodynamic Therapy (PDT) with Visudyne (verteporfin)” NCT00134667 ↗ “Verteporfin (Visudyne) Photodynamic Therapy (PDT)” NCT00390026 ↗ “Bevacizumab (Avastin), Verteporfin (Visudyne)” NCT00696592 ↗ “Visudyne® + PTK787, 500 mg/day” NCT00138632 ↗ “Visudyne (Verteporfin PDT)” NCT00574093 ↗ |
| Known as | Visudyne = verteporfin | “Visudyne = verteporfin” NCT00570193 ↗ |
| Action | Inhibit | “Its Local Inhibition With Verteporfin” NCT06944249 ↗ |
| Modality | Other / unclassified | “a photosensitizing agent in combination with laser” NCT00390026 ↗ |
| Route | Intravenous | “verteporfin (given intravenously)” NCT00049959 ↗ |
| Target | YAP1 | “The Role of YAP1 in Fibrosis Explored Through Its Local Inhibition With Verteporfin” NCT06944249 ↗ |